**Mapping enzyme activity on tissue by functional-mass spectrometry imaging**

Brett R. Hamilton\*, David L. Marshall, Nicholas R. Casewell, Robert A. Harrison, Stephen J. Blanksby, Eivind A. B. Undheim\*

Abstract: Enzymes are central components of most physiological processes, and are consequently implicated in various pathologies. High-resolution maps of enzyme activity within tissues therefore represent powerful tools for elucidating enzymatic functions in health and disease. Here, we present a novel mass spectrometry imaging (MSI) method for assaying the spatial distribution of enzymatic activity directly from tissue. MSI analysis of tissue sections exposed to phospholipid substrates produced high-resolution maps of phospholipase activity and specificity, which could subsequently be compared to histological images of the same section. Functional MSI thus represents a new and generalisable method for imaging biological activity *in situ*.

Enzymes are catalytic machines responsible for virtually every physiological process and, consequently, variations in enzyme abundance, activity, specificity, or efficacy are implicated in a wide range of pathologies.[1-5] Although changes in enzyme abundance and activity can be quantified by assaying homogenised tissue, such methods are vulnerable to averaging effects that obscure highly localised changes. High resolution spatially-resolved assays of enzyme activity would therefore present a powerful tool for elucidating or diagnosing the causes of a range of diseases.[6] Targeted imaging of enzyme activity using chemically-labelled probes [6, 7] or substrates has been demonstrated,[8] however, no single imaging modality can routinely map the distribution of enzymes on tissue while simultaneously quantifying their catalytic efficacy and selectivity.

\* Dr Brett Hamilton

Centre for Advanced Imaging, and Centre for Microscopy and Microanalysis

The University of Queensland

Brisbane QLD 4072, Australia

E-mail: b.hamilton@uq.edu.au

Dr David L. Marshall and Prof Stephen J. Blanksby

Central Analytical Research Facility, Institute for Future Environments

Queensland University of Technology

Brisbane QLD 4001, Australia

Prof Nicholas R. Casewell and Prof Robert A. Harrison

Centre for Snakebite Research & Interventions

Liverpool School of Tropical Medicine

Pembroke Place, Liverpool, L3 5QA, UK

\* Dr Eivind A. B. Undheim

Centre for Biodiversity Dynamics, Department of Biology, Norwegian University of Science and Technology, 7491, Trondheim, Norway;

Centre for Ecological and Evolutionary Synthesis, Department of Bioscience, The University of Oslo, 0316, Oslo, Norway;

Centre for Advanced Imaging, and Institute for Molecular Bioscience,

The University of Queensland

Brisbane QLD 4072, Australia

E-mail: eivind.a.b.undheim@ntnu.no

Mass spectrometry imaging (MSI)[9] partially resolves this problem through sensitive detection and high-resolution mapping of unlabelled analytes, such as spatial changes in metabolic profiles resulting from dysregulation of enzyme activity.[10] However, conventional MSI approaches yield complex spectra that are limited by incomplete structural elucidation of detected compounds, and an inability to link a specific metabolite to a unique biochemical pathway. This ambiguity makes MSI-based metabolomics an exhaustive approach for quantifying enzyme activity across tissues. Advanced MSI strategies that spatially resolve unique metabolites rely on the co-deposition of a reactive substrate during tissue preparation.[11, 12] This presents an opportunity to move beyond merely localization of biomolecules, to mapping enzymatic activity. Here, we introduce functional-mass spectrometry imaging (fMSI) for measuring the spatial distribution of enzymatic activity across tissues. We used the venom glands of the brown forest cobra (*Naja subfulva*)as our model system because its venom is known to be rich in in enzymatically active PLA2, making it ideal for development of fMSI.[13] We demonstrate that fMSI assays are well suited to profiling phospholipase A2 (PLA2) activity, and can therefore describe the spatial distribution of active PLA2 enzymes across histological sections. In principle, fMSI is transferrable to any MS-based enzymatic assay, and is thus applicable to the visualisation of many biological processes across different tissue types with micron-scale resolution.[14]

For the initial screening assay, separate solutions containing enzyme and substrate are mixed *in vitro* and infused directly into a mass spectrometer, which continually records the solution composition. To assay phospholipase activity, phosphatidylcholine (PC) substrates incorporating different fatty acids (FAs) on the glycerol backbone were selected. This enables discrimination between PLA1 and PLA2 activity, which facilitate selective ester hydrolysis at the *sn*-1 and *sn*-2 position, respectively.

**Figure 1: Mass spectrometry-based enzyme assays are sensitive and powerful.** Activity assay of porcine pancreatic PLA2 on phosphatidylcholine 34:1 isomers by nESI-MS. **A)** shows the temporal change in abundance of the substrate (PC 16:0/18:1, red) and LPC products. **B)** shows the averaged mass spectrum from the shaded area in **A**. **C)** similarly shows the depletion of PC 18:1/16:0 (red), and formation of LPCs. Averaging over the shaded area yields the mass spectrum shown in **D)**.

As shown in Figure 1, the activity of porcine pancreatic PLA2 (ppPLA2) was measured on a pair of regioisomeric glycerophospholipids incorporating palmitic and oleic acid, denoted PC 16:0/18:1 and PC 18:1/16:0 (X:Y nomenclature denotes the length and unsaturation of each FA [15]). A freshly prepared mixture of enzyme (in water) and substrate (in methanol) was infused directly into the mass spectrometer using a chip-based nano-electrospray ionization (nESI) source to eliminate sample carry-over. Extracted ion chromatograms shown in Figure 1A and 1C reveal a temporal depletion of the intact substrate and a concomitant increase in products arising from catalytic lipid hydrolysis. The rate of substrate depletion by PLA2 is dependent on the length and degree of unsaturation of the FA.[16] The major product observed upon mixing PC 16:0/18:1 with ppPLA2 (Figure 1B) is lyso-phosphatidylcholine 16:0 (LPC 16:0, green trace), arising from liberation of oleic acid from the *sn*-2 position. The time-dependent increase of a second product ion at *m/z* 522.4 (blue trace) is assigned LPC 18:1. Based on MS/MS interrogation (Supporting Information, Figure S1), both species are assigned as LPCs arising from PLA2 activity on a mixture of isomers, rather than PLA2 and PLA1 activity on a unique substrate.[17, 18] This hypothesis is consistent with the presence of PC 18:1/16:0 as an impurity in PC 16:0/18:1,[19] as confirmed by regiospecific tandem mass spectrometry experiments (Supporting Information, Figure S2).[20] A similar result is obtained for PC 18:1/16:0 in Figure 1C and Figure 1D, which demonstrates that PLA2 activity generates LPC 18:1 as the major product (blue trace), but also LPC 16:0 arising from the alternate regioisomer. Furthermore, the activity of ppPLA2 was trialled on various phospholipid substrates with similar results (e.g., PE 16:0/18:1, PC 16:0/22:6, Supporting Information, Figure S3), confirming the time-dependent conversion of the PC substrate into LPC products. These data demonstrate the feasibility of MS approaches to simultaneously measure substrate depletion and product generation in real time and with high specificity.

**Figure 2: fMSI of *N. subfulva* venom gland*,* showing the distribution of PLA2 activity against two different substrates.** (A) Optical image of a 7 m section of venom gland tissue, (B) MALDI-MSI ion map, and (C) averaged MALDI mass spectrum in the absence of lipid substrate. Application of PC 16:1/16:1 (D-F) or PC 15:0/18:1-d7 (G-I) with the MALDI matrix enables acquisition of fMSI ion maps of the substrate (blue) and PLA2 product (yellow) for each section (E, H), along with their average spectra (F, I). Scale bar represents 2 mm.

The selectivity of PLA2 activity in milked *N. subfulva* venom was screened against PC substrates to unambiguously identify the LPC products of phospholipase activity (Supporting Information, Figure S4). This revealed that MALDI induced some formation of LPC from the PC substrates, although at a much lower rate than observed by PLA2 activity. After validating the assay *in vitro*, glycerophospholipid substrates were applied to tissue sections in order to spatially map phospholipase activity by matrix-assisted laser desorption ionization (MALDI) mass spectrometry directly off the venom gland (i.e., fMSI). This experiment (Figure 2D-F) revealed that product ions arising from phospholipase activity ([LPC 16:1+H]+, m/z 494.3, yellow) can be found across the venom gland, but with some notable regional variation such as lower abundance and even small patches lacking PLA2 activity in some posterior parts of the gland. In contrast, the distribution of intact substrate ([PC 16:1/16:1+H]+, m/z 730.6, blue) is largely restricted to regions outside the tissue perimeter, where we also only observed extremely low LPC signal corresponding to a low amount of MALDI-induced LPC formation. The identity of the major product ion in Figure 2F was confirmed as enzyme-generated LPC 16:1 by an analogous experiment using a matrix-free tissue section and liquid extraction surface analysis coupled to a high resolution tandem mass spectrometer (Supporting Information, Figure S5).

To ensure that the product signals were not from endogenous LPCs, the fMSI experiment was repeated using a deuterium-labelled substrate (PC 15:0/18:1-d7) (Figure 2H). This experiment yielded significantly lower signal intensity than observed for PC 16:1/16:1, which is likely due to differences in the total amount of substrate deposited during sample preparation. Nevertheless, only the [M+H]+ ion corresponding to LPC 15:0 is observed (*m/z* 482.3; Figure 2I), thus confirming that the products are solely from PLA2 activity. Products associated with other phospholipases were not observed from *N. subfulva* venom (Supporting Information, Figure S4). Moreover, in the absence of applied substrate (Figure 2B), no lipid signals were observed (Figure 2C). Finally, adding a PLA2 inhibitor (Varespladib) prevented the formation of LPC 16:0 upon incubation of PC 16:0/18:1 with milked venom or liquid droplet extract from venom gland of *N. subfulva* (Supporting Information, Figure S6). This was also the case in micro-dissected samples from the venom gland, where we also confirmed the presence of enzymatically active PLA2 isoforms by bottom-up proteomics (Supporting Information, Figure S6)*.* This finding confirms the preservation of enzyme activity throughout histological sample preparation, and is consistent with an even distribution of PLA2 throughout the *N. subfulva* venom gland, as determined by shotgun proteomics of homogenized partitioned tissue sections (Supporting Information, Figure S7).

It is desirable to correlate the observed activity distribution with the spatial distributions of endogenous biomolecules, as well as histological features. The distribution of peptides and small proteins was therefore obtained by examining the same tissue section used for fMSI by conventional MSI (Figure 3). Venom PLA2 proteins were not detected in *N. subfulva* venom gland tissue by MSI, possibly due to their high molecular weight and low abundance relative to other venom components. Nonetheless, this analysis (Figure 3C) revealed an intriguing non-uniform distribution of masses corresponding to three-finger toxins (3FTx) that has not previously been described. It is also worth noting that this heterogeneous distribution included a particular abundance of 3FTx in the same posterior region of the gland that showed little or no PLA2 activity (Figure 2). The functional significance of these findings remains to be elucidated, however similar heterogeneous toxin distributions have been found in the venom glands of other animals, reflecting functionally distinct venoms [21, 22] or evolutionary contraints.[23] Following MSI acquisition and matrix removal, the tissue section can be stained using standard histological techniques (Figure 3A). Thus, fMSI is compatible with conventional MSI and histological workflows in biomarker discovery.

These results greatly improve our knowledge of the basic biology of the snake venom gland, because they demonstrate for the first time that PLA2 enzymes are functionally active during storage in the gland. The danger of venom enzymes to the glandular tissue is thought to be controlled by a variety of protein pre-prodomain structures and the expression of enzyme inhibitors.[24] This study suggests either that the glandular tissue is impervious to PLA2 degradation, or that the inhibitory system for controlling PLA2 bioactivity is readily disengaged, in this instance by histological processing. Either scenario raises fascinating questions regarding the co-evolution of snake venom PLA2 and the factors that prevent the degradation of the venom gland in which they are stored.

**Figure 3: MSI and histology of the *N. subfulva* venom gland post-fMSI.** **A**) Section of *N. subfulva* venom gland after paraffin removal before substrate and matrix deposition (left); a H&E stain undertaken following fMSI and MSI data acquisition and matrix removal (right). **B**) Averaged mass spectrum from MSI analysis of the same *N. subfulva* venom gland section post fMSI acquisition, showing abundant signals from three-finger toxins known to be abundant in the venom. **C**) Spatial distribution of endogenous compounds in the *N. subfulva* venom gland, including three-finger toxins with possible cytotoxic and neurotoxic activities. Intensities of extracted ions (±1 Da) from normalized spectra are shown as heat maps across the tissue section. Scale bar represents 2 mm.

There is a growing realisation of the versatility and power of MSI to map the distribution of specific biomolecules at micron-scale resolution across tissue sections.[9-12, 14, 25] Functional MSI adds to the repertoire of these capabilities by providing, for the first time, a method to map the spatial distribution of enzymatic activity. By applying substrate onto tissue sections, the type and distribution of active enzymes can be mapped through their catalytic products. Although this study used PLA2 as the model enzyme, fMSI will be generally applicable to assaying the activity of different enzymes on any MSI platform, but particularly those equipped with high mass resolution and/or tandem mass spectrometry capabilities to increase confidence in product identification. Mass spectrometry is ideally suited to conducting simultaneous and comprehensive assays across multiple enzyme classes.[26] The activities of many enzymes can also be reproduced using mimic substrates that are more suitable for analysis by mass spectrometry than native substrates due to reduced molecular weight, greater solubility, and improved detectability.[27] Taken together, fMSI will undoubtedly yield new insight into enzyme biochemistry, and the numerous roles of enzymatic activity in health and disease.

Experimental Section

See supporting information.

Acknowledgements

The authors thank Paul Rowley for snake husbandry and venom extractions, and Carsten Minten at Leica Microsystems for assistance with laser microdissections. This work was funded by the Australian Research Council (DE160101142 and DP160104025 to E.A.B.U., DP150101715 and DP190101486 to S.J.B., and LP140100832 to B.R.H.), the Norwegian Research Council (FRIPRO-YRT Fellowship no. 287462 to E.A.B.U.), the UK Medical Research Council (MR/L01839X/1 to N.R.C. and R.A.H.), and the Wellcome Trust and Royal Society (Sir Henry Dale Fellowship 200517/Z/16/Z to N.R.C.). Proteomic analyses were conducted at the Institute for Molecular Bioscience Proteomics Facility, The University of Queensland, The University of Queensland (UQ). MSI experiments were done at the Australian Microscopy & Microanalysis Research Facility, the Centre for Microscopy and Microanalysis, UQ. High mass resolution PLA2 assays were conducted at the Central Analytical Research Facility (CARF), within the QUT Institute for Future Environments.

**Keywords:** Mass Spectrometry Imaging • lipids • enzyme • functional assay • PLA2

[1] M. R. Darragh, E. L. Schneider, J. Lou, P. J. Phojanakong, C. J. Farady, J. D. Marks, B. C. Hann, C. S. Craik, *Cancer Res.* **2010**, *70*, 1505–1512.

[2] E. A. Dennis, J. Cao, Y. H. Hsu, V. Magrioti, G. Kokotos, *Chem. Rev.* **2011**, *111*, 6130–6185.

[3] S. Kang, A. G. Bader, P. K. Vogt, *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 802–807.

[4] M. M. Mohamed, B. F. Sloane, *Nat. Rev. Cancer* **2006**, *6*, 764–775.

[5] E. Wieczorek, E. Jablonska, W. Wasowicz, E. Reszka, *Tumor Biol.* **2015**, *36*, 163–175.

[6] M. Fonović, M. Bogyo, *Expert Rev. Proteomics* **2008**, *5*, 721–730.

[7] J. W. Chang, R. E. Moellering, B. F. Cravatt, *Angew. Chem. Int. Ed. Engl.* **2012**, *51*, 966–970.

[8] T. W. Bumpus, J. M. Baskin, *ACS Cent. Sci.* **2017**, *3*, 1070–1077.

[9] R. M. Caprioli, T. B. Farmer, J. Gile, *Anal. Chem.* **1997**, *69*, 4751–4760.

[10] M. R. L. Paine, B. L. J. Poad, G. B. Eijkel, D. L. Marshall, S. J. Blanksby, R. M. A. Heeren, S. R. Ellis, *Angew. Chem. Int. Ed. Engl.* **2018**, *130*, 10690–10694.

[11] A. Bednarik, S. Bolsker, J. Soltwisch, K. Dreisewerd, *Angew. Chem. Int. Ed. Engl.* **2018**, *57*, 12092–12096.

[12] F. Waldchen, B. Spengler, S. Heiles, *J. Am. Chem. Soc.* **2019**, *141*, 11816–11820.

[13] L. P. Lauridsen, A. H. Laustsen, B. Lomonte, J. M. Gutierrez, *J. Proteomics* **2017**, *150*, 98–108.

[14] M. Kompauer, S. Heiles, B. Spengler, *Nat. Methods* **2016**, *14*, 90–96.

[15] G. Liebisch, J. A. Vizcaino, H. Kofeler, M. Trotzmuller, W. J. Griffiths, G. Schmitz, F. Spener, M. J. Wakelam, *J. Lipid Res.* **2013**, *54*, 1523–1530.

[16] K. C. Batchu, S. Hänninen, S. K. Jha, M. Jeltsch, P. Somerharju, *Biochim. Biophys. Acta Mol. Cell. Biol. Lipids* **2016**, *1861*, 1597–1604.

[17] X. Han, R. W. Gross, *J. Am. Chem. Soc.* **1996**, *118*, 451–457.

[18] F.-F. Hsu, J. Turk, A. K. Thukkani, M. C. Messner, K. R. Wildsmith, D. A. Ford, *J. Mass Spectrom.* **2003**, *38*, 752–763.

[19] R. L. Kozlowski, T. W. Mitchell, S. J. Blanksby, *Sci. Rep.* **2015**, *5*, 9243.

[20] H. T. Pham, A. T. Maccarone, M. C. Thomas, J. L. Campbell, T. W. Mitchell, S. J. Blanksby, *Analyst* **2014**, *139*, 204–214.

[21] S. Dutertre, A.-H. Jin, I. Vetter, B. Hamilton, K. Sunagar, V. Lavergne, V. Dutertre, B. G. Fry, A. Antunes, D. J. Venter, P. F. Alewood, R. J. Lewis, *Nat. Commun.* **2014**, *5*, 3521.

[22] A. A. Walker, M. L. Mayhew, J. Jin, V. Herzig, E. A. B. Undheim, A. Sombke, B. G. Fry, D. J. Meritt, G. F. King, *Nat. Commun.* **2018**, *9*, 755.

[23] E. A. B. Undheim, B. R. Hamilton, N. D. Kurniawan, G. Bowlay, B. W. Cribb, D. J. Merritt, B. G. Fry, G. F. King, D. J. Venter, *Proc. Natl. Acad. Sci. U.S.A.* **2015**, *112*, 4026–4031.

[24] S. C. Wagstaff, P. Favreau, O. Cheneval, G. D. Laing, M. C. Wilkinson, R. L. Miller, R. Stocklin, R. A. Harrison, *Biochem. Biophys. Res. Commun.* **2008**, *365*, 650–656.

[25] S. R. Ellis, M. R. L. Paine, G. B. Eijkel, J. K. Pauling, P. Husen, M. W. Jervelund, M. Hermansson, C. S. Ejsing, R. M. A. Heeren, *Nat. Methods* **2018**, *15*, 515–518.

[26] D. C. Sevin, T. Fuhrer, N. Zamboni, U. Sauer, *Nat. Methods* **2017**, *14*, 187–194.

[27] H. Zhang, S. Maqsudi, A. Rainczuk, N. Duffield, J. Lawrence, F. M. Keane, D. Justa-Schuch, R. Geiss-Friedlander, M. D. Gorrell, A. N. Stephens, *FEBS J.* **2015**, *282*, 3737–3757.

**Entry for the Table of Contents**

|  |  |  |
| --- | --- | --- |
| COMMUNICATION | | |
| By bringing together the specificity of enzyme to their substrates with mass spectrometry imaging, we describe an approach which can reveal the location and efficacy of enzymatic activity in histological tissue sections with the analytical confidence of mass spectrometry detection. We herein refer to this approach as functional mass spectrometry imaging (fMSI). |  | Brett R. Hamilton\*, David L. Marshall, Nicholas R. Casewell, Robert A. Harrison, Stephen J. Blanksby, Eivind A. B. Undheim\*  Page No. – Page No.  Mapping enzyme activity on tissue by functional-mass spectrometry imaging |
|  |